return to news
  1. Gujarat Kidney and Super Speciality IPO Day 2: Check live subscription status and 10 key things to know

Market News

Gujarat Kidney and Super Speciality IPO Day 2: Check live subscription status and 10 key things to know

Kamal Joshi

3 min read | Updated on December 23, 2025, 08:06 IST

Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

Gujarat Kidney and Super Speciality IPO: The ₹250.80 crore IPO consists solely of a fresh issuance of 2.20 crore shares. There is no offer for sale (OFS) component.

Gujarat Kidney and Super Speciality IPO has set aside 75% of the issue for QIBs, 15% for NIIs and 10% for retail investors. | Image: Shutterstock

Gujarat Kidney and Super Speciality IPO has set aside 75% of the issue for QIBs, 15% for NIIs and 10% for retail investors. | Image: Shutterstock

Gujarat Kidney and Super Speciality IPO: The initial public offering of Gujarat-based healthcare company Gujarat Kidney and Super Speciality has received a robust response from investors. The subscription details for the second day of bidding will be available post 10 am.

Open FREE Demat Account within minutes!
Join now

As of Day 1, the issue was booked 1.47 times, with bids for 1,94,73,280 shares compared to 1,32,26,880 shares on offer, according to the NSE data.

The category for retail investors attracted 4.70 times subscription, while the portion for non-institutional investors (NIIs) got subscribed 1.97 times. The quota for qualified institutional buyers (QIBs) fetched a 34% subscription.

Gujarat Kidney and Super Speciality IPO: 10 key points to know

  • Gujarat Kidney and Super Speciality IPO subscription period: The initial share sale is live from December 22 to December 24.
  • Anchor round: Before the IPO, the company raised ₹100.01 crore from anchor investors, including Nexus Global Opportunities Fund, Sunrise Investment Opportunities Fund, Venus Investments and Khandelwal Finance Pvt Ltd.
  • IPO offer structure: The ₹250.80 crore IPO consists solely of a fresh issuance of 2.20 crore shares.
  • Objectives: The fresh issue proceeds will be used for the proposed acquisition of Parekhs Hospital in Ahmedabad and part-payment for the already acquired "Ashwini Medical Centre", establishing a new hospital in Vadodara, buying robotics equipment, debt repayment, inorganic growth and general corporate purposes.
  • Gujarat Kidney and Super Speciality IPO price band: The price range has been set at ₹108 to ₹114 per share.
  • Reservation: The company has set aside 75% of the issue for QIBs, 15% for NIIs and 10% for retail investors.
  • Gujarat Kidney and Super Speciality IPO lot size: Retail investors can apply for at least 128 shares and in multiples thereof.
  • Book-running lead manager and registrar: Nirbhay Capital Services Private Limited is the only book-running lead manager of the issue. MUFG Intime India serves as the registrar.
  • Gujarat Kidney and Super Speciality IPO allotment date: The allotment is expected to be finalised on December 26.
  • Listing date: The listing on the stock exchanges will take place on December 29.

Gujarat Kidney and Super Speciality IPO GMP

According to investorgain.com and media reports, Gujarat Kidney & Super Speciality's unlisted shares are trading at ₹118, reflecting a grey market premium of 3.51% over the upper price band of ₹114.
Disclaimer: Grey Market Premium (GMP) is not regulated or recommended by the stock exchanges or SEBI. Upstox does not endorse or facilitate trading in the grey market. Investors are advised to conduct their own research or consult an expert before making any investment decisions.
To learn more about IPOs, their listings, schedules, and upcoming IPOs, visit our page.

To add Upstox News as your preferred source on Google, click here.
SIP
Consistency beats timing.
promotion image

About The Author

Kamal Joshi
Kamal Joshi is a business journalist who covers industries, markets, and IPOs. He is passionate about breaking news and enjoys playing tennis, especially flexing his backhand. He was previously associated with Republic TV and LatestLY.

Next Story